Laurus Labs Annual Report Analysis - Scaling Up New Levers To Accelerate Growth: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Laurus Labs Ltd.’s annual report analysis indicates a sharp improvement in return on equity, led by a strong head-start in finished dosage forms, improving operating profit, and a reduced interest rate.
Since its journey from anti-retroviral active pharmaceutical ingredient to a fully integrated pharmaceutical company over FY06–21, Laurus Labs is on the path to strengthening its capabilities/capacity in contract development and manufacturing operations – the synthesis as well as biotechnology space.
Accordingly, the company is investing Rs 15–17 billion in building research and development centers and greenfield/brownfield expansions for a meaningful commercial benefit from FY23.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.